A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis

Main measures

• The primary efficacy endpoint is the number of new or enlarged gadolinium contrast enhancing lesions (Gd-CELs) on monthly brain MRIs collected between Weeks 8 to 24 in daclizumab- vs. placebo-treated patients.

  MRI lesions

• LTS18002

  Phase 3 · Not yet recruiting

  Still running

• FREXALT

  Phase 3 · Running, not recruiting

  Still running

• LITMUS

  Not a drug-phase study · Completed (inferred)

  Results posted, no main test reported

• Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with RMS

  Phase 2 · Stopped early

  Stopped early

• SUSTAIN

  Phase 3 · Stopped early

  Stopped early

• ZEUS

  Not a drug-phase study · Stopped

  Stopped early

1. 2026-10-28In scope changed from true to false

1. Started

   Jul 2005